MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways

Sun,Pengcheng; Wang,Lu; Lu,Yunhan; Liu,Yuwei; Li,Lechen; Yin,Luyao; Zhang,Cheng; Zhao,Weiming; Shen,Baozhong; Xu,Wanhai

doi:10.3892/ijo.2016.3608

MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways

Authors:
- Pengcheng Sun
- Lu Wang
- Yunhan Lu
- Yuwei Liu
- Lechen Li
- Luyao Yin
- Cheng Zhang
- Weiming Zhao
- Baozhong Shen
- Wanhai Xu
View Affiliations

Affiliations: Department of Urology, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Urology, The First Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Radiology, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: July 6, 2016 https://doi.org/10.3892/ijo.2016.3608
Pages: 1155-1163

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence indicates that dysregulation of miR-195 may contribute to the occurrence and development of multiple types of human malignancies. However, the function and the mechanism of miR-195 in clear cell renal cell carcinoma (ccRCC) are still not fully understood. In the present study, we used qRT-PCR to detect the expression of miR-195 in ccRCC tissues and normal kidney tissues. MTT assay was performed to detect the cell viability of miR-195. Migration and invasion were evaluated by Transwell migration and Matrigel invasion assays, respectively. Additionally, apoptosis levels were evaluated using TUNEL assays, and signaling pathway changes were determined by western blot analysis. We observed that miR-195 was downregulated in clear cell renal cell carcinoma samples compared with normal renal samples. We identified that overexpression of miR-195 inhibited ACHN cell viability, migration, invasion, and it also induced cell apoptosis by targeting VEGFR2 via PI3K/Akt and Raf/MEK/ERK signaling pathways. These findings indicate that miR-195 has a tumor suppressive role in ACHN cells and miR-195 may be a promising candidate target for prevention and treatment of renal cell carcinoma.

View Figures

View References

1	Rasmussen F: Metastatic renal cell cancer. Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
2	Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010. View Article : Google Scholar : PubMed/NCBI
3	Lujambio A and Lowe SW: The microcosmos of cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
4	Saxena S, Jónsson ZO and Dutta A: Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem. 278:44312–44319. 2003. View Article : Google Scholar : PubMed/NCBI
5	Jia LF, Wei SB, Gong K, Gan YH and Yu GY: Prognostic implications of micoRNA miR-195 expression in human tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
6	Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
7	Heneghan HM, Miller N, Kelly R, Newell J and Kerin MJ: Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 15:673–682. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW and Ahn WS: Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI
9	Slaby O, Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M and Vyzula R: Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer. 51:707–716. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hardwick JM and Soane L: Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol. 5:a0087222013. View Article : Google Scholar : PubMed/NCBI
11	Davids MS and Letai A: Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 30:3127–3135. 2012. View Article : Google Scholar : PubMed/NCBI
12	Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
13	Antonsson B: Bax and other pro-apoptotic Bcl-2 family ‘killer-proteins’ and their victim the mitochondrion. Cell Tissue Res. 306:347–361. 2001. View Article : Google Scholar : PubMed/NCBI
14	Li CL, Chang L, Guo L, Zhao D, Liu HB, Wang QS, Zhang P, Du WZ, Liu X, Zhang HT, et al: β-elemene induces caspase-dependent apoptosis in human glioma cells in vitro through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Asian Pac J Cancer Prev. 15:10407–10412. 2014. View Article : Google Scholar
15	Zhang W, Ha M, Gong Y, Xu Y, Dong N and Yuan Y: Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways. Oncol Rep. 24:1585–1592. 2010.PubMed/NCBI
16	Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK and Stoeltzing O: Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther. 7:3509–3518. 2008. View Article : Google Scholar : PubMed/NCBI
17	Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
18	Pal HC1, Sharma S, Strickland LR, Agarwal J, Athar M, Elmets CA and Afaq F: Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One. 8:e772702013. View Article : Google Scholar : PubMed/NCBI
19	Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N and Shibuya M: Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA. 102:1076–1081. 2005. View Article : Google Scholar : PubMed/NCBI
20	Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G and Aprile G: Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2:1232014.
21	Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar
22	Conti A, Santoni M, Amantini C, Burattini L, Berardi R, Santoni G, Cascinu S and Muzzonigro G: Progress of molecular targeted therapies for advanced renal cell carcinoma. BioMed Res Int. 2013:4191762013. View Article : Google Scholar : PubMed/NCBI
23	Troppmair J and Rapp UR: Raf and the road to cell survival: A tale of bad spells, ring bearers and detours. Biochem Pharmacol. 66:1341–1345. 2003. View Article : Google Scholar : PubMed/NCBI
24	Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 104:2323–2333. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sridhar SS, Hedley D and Siu LL: Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 4:677–685. 2005. View Article : Google Scholar : PubMed/NCBI
26	Chan CH, Jo U, Kohrman A, Rezaeian AH, Chou PC, Logothetis C and Lin HK: Posttranslational regulation of Akt in human cancer. Cell Biosci. 4:592014. View Article : Google Scholar : PubMed/NCBI
27	Shaul YD and Seger R: The MEK/ERK cascade: From signaling specificity to diverse functions. Biochim Biophys Acta. 1773:1213–1226. 2007. View Article : Google Scholar
28	Walker C: Molecular genetics of renal carcinogenesis. Toxicol Pathol. 26:113–120. 1998. View Article : Google Scholar : PubMed/NCBI
29	Bussolati B, Satolli MA and Camussi G: The role of angiogenesis in renal carcinoma. G Ital Nefrol. 25:297–305. 2008.(In Italian). PubMed/NCBI
30	Redova M, Svoboda M and Slaby O: MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
31	Ma L and Qu L: The function of microRNAs in renal development and pathophysiology. J Genet Genomics. 40:143–152. 2013. View Article : Google Scholar : PubMed/NCBI
32	Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
33	Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 32:1910–1920. 2013. View Article : Google Scholar :
34	Kim WY and Kaelin WG Jr: Molecular pathways in renal cell carcinoma - rationale for targeted treatment. Semin Oncol. 33:588–595. 2006. View Article : Google Scholar : PubMed/NCBI
35	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
36	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
37	Reuter CW, Morgan MA, Grünwald V, Herrmann TR, Burchardt M and Ganser A: Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World J Urol. 25:59–72. 2007. View Article : Google Scholar : PubMed/NCBI
38	Rini BI and Rathmell WK: Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res. 13:741s–746s. 2007. View Article : Google Scholar : PubMed/NCBI